BioXcel Therapeutics Reports Positive Safety Data for SERENITY At-Home Pivotal Phase 3 Trial

BioXcel Therapeutics (BTAI) discussed the SERENITY At-Home Pivotal Phase 3 Safety Trial Results Conference. The company's CEO, Vimal Mehta, and Clinical Professor of Psychiatry and Behavioral Sciences, Leslie Citrome, presented the data, which showed positive primary safety results and top-line exploratory efficacy results for the management of acute agitation. The mission is to transform patient care by bringing a new treatment option for acute agitation to the home setting, easing the burden for patients and families.